{"id":"W1764703361","doi":"10.1182/blood.v124.21.629.629","title":"Brentuximab Vedotin Monotherapy in DLBCL Patients with Undetectable CD30: Preliminary Results from a Phase 2 Study","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Brentuximab vedotin; Medicine; CD30; Internal medicine; Oncology; Rituximab; Diffuse large B-cell lymphoma; Chemotherapy regimen; Lymphoma; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001560359,0.0009620755,0.001660558,0.0002514238,0.000301794,0.0009075089,0.0004686425,0.0007682299,0.001705789],"category_scores_gemma":[0.0009002909,0.0003640196,0.001005187,0.0002761795,0.0005291369,0.000615865,0.0002981773,0.001962202,0.0004836971],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006284351,"about_ca_system_score_gemma":0.0007692028,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007691592,"about_ca_topic_score_gemma":0.001672894,"domain_scores_codex":[0.999582,0.000191454,0.00002814271,0.00006296724,0.00005029708,0.00008522555],"domain_scores_gemma":[0.9994677,0.0001276055,0.00007566937,0.00004890798,0.00004922773,0.0002309533],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5015607,0.1116561,0.0185496,0.001818976,0.003150778,0.001568314,0.0008528811,0.00352986,0.1489745,0.0003323589,0.00503993,0.2029659],"study_design_scores_gemma":[0.3677953,0.5816425,0.03345334,0.00009850423,0.0012909,0.001153292,0.0001373758,0.001771,0.006577802,0.0003651119,0.005658076,0.00005677667],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917514,0.004478951,0.0005751895,0.0002921598,0.00006384178,0.001242302,0.0006118393,0.00005893453,0.0009254775],"genre_scores_gemma":[0.9917526,0.002695437,0.001075482,0.0007310203,0.0001062628,0.001043868,0.001617696,0.00001986405,0.0009577302],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001705789,"threshold_uncertainty_score":0.008252084,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008682233837594403,"score_gpt":0.2445351656179477,"score_spread":0.2358529317803534,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}